Skip to main content

An Evaluation of Pharmacological Strategies for the Prevention and Treatment of Acute Renal Failure

Drugs volume 59, pages 79–91 (2000)Cite this article

Abstract

Acute renal failure (ARF) occurs frequently in hospitalised patients, and is associated with significant morbidity and mortality. The most common and generalised forms of acute renal failure are pre-renal conditions and intra-renal acute tubular necrosis (ATN). Pre-renal ARF in its pure state should be entirely reversible by restoring renal perfusion, but in some cases ATN has already occurred. ATN remains a more vexing problem, and is seen most often with hypotension, perioperative or systemic inflammatory stresses, radiocontrast administration, and exposure to nephrotoxins. Among the available pharmacological options for prevention or treatment of ATN, there is a remarkable lack of definitive evidence supporting specific therapy in any setting. Although loop diuretics, mannitol, and dopamine are frequently used for prevention and/or treatment of ATN, clinical studies have failed to prove value. Other drugs with theoretical value, specifically atrial natriuretic peptide analogues, adenosine blockers, and calcium antagonists, have been insufficiently studied to recommend use. Other pharmacological options may arise in the future. Ensuring adequate intravascular fluid volume remains the only approach to managing ATN which can be considered relatively effective and safe. Given the abundant theoretical basis for the prevention and treatment of ATN with drugs, well conducted clinical studies with relevant outcome measures are clearly warranted.

This is a preview of subscription content, access via your institution.

Access options

Buy single article

Instant access to the full article PDF.

49,54 €

Price includes VAT (Finland)
Tax calculation will be finalised during checkout.

Table I
Fig. 1

References

  1. Nissenson AR. Acute renal failure: definition and pathogenesis. Kidney Int 1998; 53 Suppl. 66: S7–10

    Google Scholar 

  2. Knaus WA, Wagner DP, Draper EA, et al. The APACHE III prognostic system. Risk prediction of hospital mortality for critically ill hospitalized adults. Chest 1991; 100: 1619–36

    CAS  Google Scholar 

  3. Hou SH, Bushinsky D A, Wish JB, et al. Hospital-acquired renal insufficiency: aprospective study. Am J Med 1983; 74: 243–8

    PubMed  Article  CAS  Google Scholar 

  4. Brivet FG, Kleinknecht DJ, Loirat P, French Study Group on Acute Renal Failure, et al. Acute renal failure in intensive care units: causes, outcomes and prognostic factors of hospital mortality: a prospective multicenter study. Crit Care Med 1996; 24: 192–8

    PubMed  Article  CAS  Google Scholar 

  5. Bellomo R, Ronco C. The changing pattern of severe acute renal failure. Nephrology 1991; 2: 602–10

    Google Scholar 

  6. McCullough PA, Wolyn R, Rocher LL, et al. Acute renal failure after coronary intervention: incidence, risk factors, and relationship to mortality. Am JMed 1997; 103: 368–75

    CAS  Google Scholar 

  7. Myers BD, Moran SM. Hemodynamically mediated acute renal failure. N Engl J Med 1986; 314: 97–100

    PubMed  Article  CAS  Google Scholar 

  8. Wiecek A, Zeier M, Ritz E. Role of infection in the genesis of acute renal failure. Nephrol Dial Transplant 1994; 9 Suppl. 4: 40–4

    PubMed  Google Scholar 

  9. Ward MM. Factors predictive of acute renal failure in rhabdomyolysis. Arch Intern Med 1988; 148: 1553–7

    PubMed  Article  CAS  Google Scholar 

  10. Kahlmeter G, Dahlager JI. Aminoglycoside toxicity: a review of clinical studies published between 1975 and 1982. J Antimicrob Chemother 1984; 13 Suppl. A: 9–22

    PubMed  Article  Google Scholar 

  11. Butler WT, Bennett JE, Ailing DW, et al. Nephrotoxicity of amphotericin B, early and late events in 81 patients. Ann Intern Med 1964; 61: 175–87

    PubMed  CAS  Google Scholar 

  12. Tran DD, Oe PL, de Fijter CWH, et al. Acute renal failure in patients with acute pancreatitis: prevalence, risk factors, and outcome. Nephrol Dial Transplant 1993; 8: 1079–84

    PubMed  CAS  Google Scholar 

  13. Heyman SN, Rosen S, Brezis M. The renal medulla: life at the edge of anoxia. Blood Purif 1997; 15: 232–8

    PubMed  Article  CAS  Google Scholar 

  14. Heyman SN, Fuchs S, Brezis M. The role of medullary ischemia in acute renal failure. New Horiz 1995; 3(4): 597–607

    PubMed  CAS  Google Scholar 

  15. Osswald H, Muhlbauer B, Schenk F. Adenosine mediates tubuloglomerular feedback response: an element of metabolic control of kidney function. Kidney Int 1991 Jun; 39 Suppl. 32: S128–31

    Google Scholar 

  16. Agmon Y, Dinour D, Brezis M. Disparate effects of adenosine A1- and A2-receptor agonists on intrarenal blood flow. Am J Physiol 1993; 265 (6 Pt 2): F802–6

    PubMed  CAS  Google Scholar 

  17. Navar LG, Champion WJ, Thomas CE. Effects of calcium channel blockade on renal vascular resistance responses to changes in perfusion pressure and angiotensin-converting enzyme inhibition in dogs. Circ Res 1986 Jun; 58(6): 874–81

    PubMed  Article  CAS  Google Scholar 

  18. Thurau K, Boylan JW. Acute renal success. The unexpected logic of oliguria in acute renal failure. Am J Med 1976 Sep; 61(3): 308–15

    CAS  Google Scholar 

  19. Oken DE. Hemodynamic basis for human acute renal failure (vasomotor nephropathy). Am J Med 1984 Apr; 76(4): 702–10

    PubMed  Article  CAS  Google Scholar 

  20. Barret BJ. Contrast nephrotoxicity. J Am Soc Nephrol 1994; 5: 125–37

    Google Scholar 

  21. Solomon R, Werner C, Mann D, et al. Effects of saline, mannitol, and furosemide to prevent acute decreases in renal function induced by radiocontrast agents. N Engl J Med 1994; 33: 1416–20

    Article  Google Scholar 

  22. Heyman SN, Brezis M, Epstien FH, et al. Early renal medullary hypoxic injury from radiocontrast and indomethacin. Kidney Int 1991; 40: 632–42

    PubMed  Article  CAS  Google Scholar 

  23. Weisberg LS, Kurnik PB, Kurnik BR. Dopamine and renal blood flow in radiocontrast-induced nephropathy in humans. Ren Fail 1993; 15: 61–8

    PubMed  Article  CAS  Google Scholar 

  24. Larson TS, Hudson K, Mertz JI, et al. Renal vasoconstrictive response to contrast medium: the role of sodium balance and the renin-angiotensin system. J Lab Clin Med 1983 Mar; 101(3): 385–91

    PubMed  CAS  Google Scholar 

  25. Kellum JA. Endotoxin and renal blood flow. Blood Purif 1997; 15(4-6): 286–91

    PubMed  Article  CAS  Google Scholar 

  26. Westberg G, Shultz PJ, Raij L. Exogenous nitric oxide prevents endotoxin-induced glomerular thrombosis in rats. Kidney Int 1994; 46(3): 711–6

    PubMed  Article  CAS  Google Scholar 

  27. Heyman SN, Rosen S, Fuchs S, et al. Myoglobinuric acute renal failure in the rat: a role for medullary hypoperfusion, hypoxia, and tubular obstruction. J Am Soc Nephrol 1996; 7(7): 1066–74

    PubMed  CAS  Google Scholar 

  28. Zager RA. Rhabdomyolysis and myohemoglobinuric acute renal failure. Kidney Int 1996; 49(2): 314–26

    PubMed  Article  CAS  Google Scholar 

  29. Better OS, Stein JH. Early management of shock and prophylaxis of acute renal failure in traumatic rhabdomyolysis. N Engl J Med 1990; 322: 825–9

    PubMed  Article  CAS  Google Scholar 

  30. Rodicio JL, Morales JM, Alcazar JM, et al. Calcium antagonists and renal protection. JHypertens 1993 Mar; 11 Suppl. 1: S49–53

    Article  CAS  Google Scholar 

  31. Soper CP, Latif AB, Bending MR. Amelioration of hepatorenal syndrome with selective endothelin-A antagonist. Lancet 1996 Jun 29; 347(9018): 1842–3

    PubMed  Article  CAS  Google Scholar 

  32. Salo J, Gines A, Quer JC, et al. Renal and neurohormonal changes following simultaneous administration of systemic vasoconstrictors and dopamine or prostacyclin in cirrhotic patients with hepatorenal syndrome. J Hepatol 1996 Dec; 25(6): 916–23

    PubMed  Article  CAS  Google Scholar 

  33. Guevara M, Gines P, Fernandez-Esparrach G, et al. Reversibility of hepatorenal syndrome by prolonged administration of ornipressin and plasma volume expansion. Hepatology 1998 Jan; 27(1): 35–41

    PubMed  Article  CAS  Google Scholar 

  34. Prins JM, Buller HR, Kuijper EJ, et al. Once versus thrice daily gentamicin in patients with serious infections. Lancet 1993; 341: 335–9

    PubMed  Article  CAS  Google Scholar 

  35. Sawaya BP, Briggs JP, Schnermann J. Amphotericin B nephrotoxicity: the adverse consequences of altered membrane properties. J Am Soc Nephrol 1995 Aug; 6(2): 154–64

    PubMed  CAS  Google Scholar 

  36. Sabbatini M, De Nicola L, Sansone G, et al. Renal hypoperfusion as the primary cause of cyclosporin-induced nephropathy. Nephrol Dial Transplant 1993; 8(9): 794–7

    PubMed  CAS  Google Scholar 

  37. Brezis M, Rosen S, Silva P, et al. Transport activity modifies the ascending limb damage in isolated perfused kidney. Kidney Int 1984; 25: 65–72

    PubMed  Article  CAS  Google Scholar 

  38. Shilliday I, Allison ME. Diuretics in acute renal failure. Ren Fail 1994; 16: 3–17

    PubMed  Article  CAS  Google Scholar 

  39. Stein JH. Acute renal failure: lessons from pathophysiology. West J Med 1992; 156: 176–82

    PubMed  CAS  Google Scholar 

  40. Kellum JA. Use of diuretics in the acute care setting. Kidney Int 1998; 53 Suppl. 66: S67–70

    Google Scholar 

  41. Hager B, Betschart M, Krapf R. Effect of postoperative intravenous loop diuretic on renal function after major surgery. Schweiz Med Wochenschr 1996; 126: 666–73

    PubMed  CAS  Google Scholar 

  42. Weinstein JM, Heyman S, Brezis M. Potential deleterious effect of furosemide in radiocontrast nephropathy. Nephron 1992; 62(4): 413–5

    PubMed  Article  CAS  Google Scholar 

  43. Brown RS. Renal dysfunction in the surgical patient: maintenance of high output state with furosemide. Crit Care Med 1979; 7: 63–8

    PubMed  Article  CAS  Google Scholar 

  44. Kleinknecht D, Ganeval D, Gonzales-Duque LA, et al. Furosemide in acute oliguric renal failure. A controlled trial. Nephron 1976; 17: 51–8

    CAS  Google Scholar 

  45. Brown CB, Ogg CS, Cameron JS. High dose furosemide in acute renal failure: a controlled trial. Clin Nephrol 1981; 15: 90–6

    PubMed  CAS  Google Scholar 

  46. Shilliday IR, Quinn KJ, Allison ME. Loop diuretics in the management of acute renal failure: a prospective, double-blind, placebo-controlled, randomized study. Nephrol Dial Transplant 1997; 12(12): 2592–6

    PubMed  Article  CAS  Google Scholar 

  47. Rudy DW, Voelker JR, Greene PK, et al. Loop diuretics for chronic renal insufficiency: a continuous infusion is more efficacious than bolus therapy. Ann Intern Med 1991; 115: 360–6

    PubMed  CAS  Google Scholar 

  48. Brezis M, Agmon Y, Epstein FH. Determinants of intrarenal oxygenation. I. Effects of diuretics. Am J Physiol 1994; 267 (6 Pt 2): F1059–62

    PubMed  CAS  Google Scholar 

  49. Beall AC, Holman MR, Morris GC, et al. Mannitol-induced osmotic diuresis during vascular surgery. Arch Surg 1963; 86: 34–42

    Article  CAS  Google Scholar 

  50. Powers SR, Boba A, Hostnik W, et al. Prevention of postoperative acute renal failure with mannitol in 100 cases. Surgery 1964; 35: 15–23

    Google Scholar 

  51. Ip-Yam PC, Murphy S, Baines M, et al. Renal function and proteinuria after cardiopulmonary bypass: the effects of temperature and mannitol. Anesth Analg 1994; 78: 842–7

    PubMed  Article  CAS  Google Scholar 

  52. Gubern JM, Sancho JJ, Simo J, et al. A randomized trial on the effect of mannitol on postoperative renal function in patients with obstructive jaundice. Surgery 1988; 103: 39–44

    PubMed  CAS  Google Scholar 

  53. Ron D, Taitelman U, Michaelson M, et al. Prevention of acute renal failure in traumatic rhabdomyolysis. Arch Intern Med 1984 Feb; 144(2): 277–80

    PubMed  Article  CAS  Google Scholar 

  54. Homsi E, Barreiro MF, Orlando JM, et al. Prophylaxis of acute renal failure in patients with rhabdomyolyis. Ren Fail 1997; 19: 283–8

    PubMed  Article  CAS  Google Scholar 

  55. Better OS, Zinman C, Reis DN, et al. Hypertonic mannitol ameliorates intracompartmental tamponade in model compartment syndrome in the dog. Nephron 1991; 58(3): 344–6

    PubMed  Article  CAS  Google Scholar 

  56. Kellum JA. The use of diuretics and dopamine in acute renal failure: a systematic review of the evidence. Crit Care 1997; 1: 53–9

    PubMed  Article  Google Scholar 

  57. Seri I, Kone BC, Gullans SR, et al. Locally formed dopamine inhibits Na-K-ATPase activity in rat renal cortical tubule cells. Am J Physiol 1988; 255: F666–73

    PubMed  CAS  Google Scholar 

  58. Heyman SN, Kaminski N, Brezis M. Dopamine increases renal medullary blood flow without improving regional hypoxia. Exp Nephrol 1995; 3(6): 331–7

    PubMed  CAS  Google Scholar 

  59. Olsen NV, Hamsen JM, Ladefoged SD, et al. Renal tubular reabsorption of sodium and water during infusion of low-dose dopamine in normal man. Clin Sci 1990; 78: 503–7

    PubMed  CAS  Google Scholar 

  60. Segal JM, Phang PT, Walley KR. Low-dose dopamine hastens onset of gut ischemia in a porcine model of hemorrhagic shock. J Appl Physiol 1992; 73(3): 1159–64

    PubMed  CAS  Google Scholar 

  61. Greene S, Smith J. Dopamine gangrene [letter]. N Engl J Med 1976; 294: 114

    PubMed  Article  CAS  Google Scholar 

  62. Flancbaum L, Choban PS, Dasta JF. Quantitative effects of low-dose dopamine on urine output in oliguric surgical intensive care unit patients. Crit Care Med 1994; 22: 61–6

    PubMed  CAS  Google Scholar 

  63. Lherm T, Troche G, Rossignol M, et al. Renal effects of low-dose dopamine in patients with sepsis syndrome or septic shock treated with catecholamines. Intensive Care Med 1996; 22: 213–9

    PubMed  Article  CAS  Google Scholar 

  64. Hall KA, Wong RW, Hunter GC, et al. Contrast-induced nephrotoxicity: the effects of vasodilator therapy. J Surg Res 1992; 53: 317–20

    PubMed  Article  CAS  Google Scholar 

  65. Poison RJ, Park GR, Lindop MJ, et al. The prevention of renal impairment in patients undergoing orthotopic liver grafting by infusion of low dose dopamine. Anaesthesia 1987; 42: 15–9

    Article  Google Scholar 

  66. Swygert TH, Roberts LC, Valek TR, et al. Effect of intraoperative low-dose dopamine on renal function in liver transplant recipients. Anesthesiology 1991; 75: 571–6

    PubMed  Article  CAS  Google Scholar 

  67. Palmieri G, Morabito A, Lauria R, et al. Low-dose dopamine induces early recovery of recombinant interleukin-2 impaired renal function. Eur J Cancer 1993; 29A: 1119–22

    PubMed  Article  CAS  Google Scholar 

  68. Duke GJ, Briedis JH, Weaver RA. Renal support in critically ill patients: low-dose dopamine or low-dose dobutamine? Crit Care Med 1994; 22(12): 1919–25

    PubMed  CAS  Google Scholar 

  69. Denton MD, Chertow GM, Brady HR. ‘Renal-dose’ dopamine for the treatment of acute renal failure: scientific rationale, experimental studies, and clinical trials. Kidney Int 1996; 49: 4–14

    Article  Google Scholar 

  70. Hoogenberg K, Smit AJ, Girbes AR. Effects of low-dose dopamine on renal and systemic hemodynamics during incremental norepinephrine infusion in healthy volunteers. Crit Care Med 1998 Feb; 26(2): 260–5

    PubMed  Article  CAS  Google Scholar 

  71. Bellomo R, Kellum JA, Wisniewski SR, et al. Effects of norepinephrine on the renal vasculature in normal and endotoxemic dogs. Am J Respir Crit Care Med 1999 Apr; 159 (4 Pt 1): 1186–92

    PubMed  CAS  Google Scholar 

  72. Shaw SG, Weidmann P, Hodler J, et al. Atrial natriuretic peptide protects against acute ischemic renal failure in the rat. J Clin Invest 1987 Nov; 80(5): 1232–7

    PubMed  Article  CAS  Google Scholar 

  73. Rahman SN, Kim GE, Mathew AS, et al. Effects of atrial natriuretic peptide in clinical acute renal failure. Kidney Int 1994 Jun; 45(6): 1731–8

    PubMed  Article  CAS  Google Scholar 

  74. Allgren RL, Marbury TC, Rahman SN, et al. Anaritide in acute tubular necrosis: Auriculin Anaritide Acute Renal Failure Study Group. N Engl J Med 1997 Mar 20; 336(12): 828–34

    PubMed  Article  CAS  Google Scholar 

  75. Weisberg LS, Kurnik PB, Kurnik BR. Risk of radiocontrast nephropathy in patients with and without diabetes mellitus. Kidney Int 1994 Jan; 45(1): 259–65

    PubMed  Article  CAS  Google Scholar 

  76. Meyer M, Richter R, Forssmann WG. Urodilatin, a natriuretic peptide with clinical implications. Eur J Med Res 1998 Feb 21; 3(1-2): 103–10

    PubMed  CAS  Google Scholar 

  77. Langrehr JM, Kahl A, Meyer M, et al. Prophylactic use of low-dose urodilatin for prevention of renal impairment following liver transplantation: a randomized placebo-controlled study. Clin Transplant 1997 Dec; 11(6): 593–8

    PubMed  CAS  Google Scholar 

  78. Meyer M, Wiebe K, Wahlers T, et al. Urodilatin as a new drug for the therapy of acute renal failure following cardiac surgery. Clin Exp Pharmacol Physiol 1997 May; 24(5): 374–6

    PubMed  Article  CAS  Google Scholar 

  79. Arend LJ, Bakris GL, Burnett Jr JC, et al. Role for intrarenal adenosine in the renal hemodynamic response to contrast media. J Lab Clin Med 1987 Oct; 110(4): 406–11

    PubMed  CAS  Google Scholar 

  80. Erley CM, Duda SH, Schlepckow S, et al. Adenosine antagonist theophylline prevents the reduction of glomerular filtration rate after contrast media application. Kidney Int 1994 May; 45(5): 1425–31

    PubMed  Article  CAS  Google Scholar 

  81. Kolonko A, Wiecek A, Kokot F. The nonselective adenosine antagonist theophylline does prevent renal dysfunction induced by radiographic contrast agents. J Nephrol 1998 May–Jun; 11(3): 151–6

    PubMed  CAS  Google Scholar 

  82. Rodicio JL, Campo C, Ruilope LM. Renal effects of calcium antagonists. Nephrol Dial Transplant 1995 Oct; 10 Suppl. 9: 17–22

    PubMed  Google Scholar 

  83. Leonetti G, Rappelli A. Are there differences in the renal effects of calcium antagonists? J Hypertens 1993 Mar; 11 Suppl. 1: S45–8

    Article  CAS  Google Scholar 

  84. Pearce CJ, Wallin JD. Calcium antagonists and the kidney. New Horiz 1996 Feb; 4(1): 123–8

    PubMed  CAS  Google Scholar 

  85. Bakris GL, Burnett Jr JC. A role for calcium in radiocontrast-induced reductions in renal hemodynamics. Kidney Int 1985 Feb; 27(2): 465–8

    PubMed  Article  CAS  Google Scholar 

  86. Neumayer HH, Junge W, Kufner A, et al. Prevention of radio-contrast-media-induced nephrotoxicity by the calcium channel blocker nitrendipine: a prospective randomised clinical trial. Nephrol Dial Transplant 1989; 4(12): 1030–6

    PubMed  CAS  Google Scholar 

  87. Russo D, Testa A, Delia Volpe L, et al. Randomised prospective study on renal effects of two different contrast media in humans: protective role of a calcium channel blocker. Nephron 1990; 55(3): 254–7

    PubMed  Article  CAS  Google Scholar 

  88. Cacoub P, Deray G, Baumelou A, et al. No evidence for protective effects of nifedipine against radiocontrast-induced acute renal failure. Clin Nephrol 1988 Apr; 29(4): 215–6

    PubMed  CAS  Google Scholar 

  89. Wagner K, Albrecht S, Neumayer HH. Prevention of post-transplant acute tubular necrosis by the calcium antagonist diltiazem: a prospective randomized study. Am J Nephrol 1987; 7(4): 287–91

    PubMed  Article  CAS  Google Scholar 

  90. Morales JM, Andres A, Rodriguez Paternina E, et al. Calcium antagonist therapy prevents chronic cyclosporine nephrotoxicity after renal transplantation: a prospective study. Transplant Proc 1992 Feb; 24(1): 89–91

    PubMed  CAS  Google Scholar 

  91. Neumayer HH, Kunzendorf U, Schreiber M. Protective effects of calcium antagonists in human renal transplantation. Kidney Int 1992 May; 41 Suppl. 36: S87–93

    Google Scholar 

  92. Yee GC, McGuire TR. Pharmacokinetic drug interactions with cyclosporin(Pt I). Clin Pharmacokinet 1990 Oct; 19(4): 319–32

    PubMed  Article  CAS  Google Scholar 

  93. Edelstein CL, Ling H, Wangsiripaisan A, et al. Emerging therapies for acute renal failure. Am J Kidney Dis 1997; 30 (5 Suppl. 4): S89–95

    PubMed  Article  CAS  Google Scholar 

  94. Lake EW, Humes HD. Acute renal failure: directed therapy to enhance renal tubular regeneration. Semin Nephrol 1994 Jan; 14(1): 83–97

    PubMed  Google Scholar 

Download references

Author information

Affiliations

  1. Division of Critical Care Medicine, University of Pittsburgh Medical Center, Scaife Hall, Room 615, 3550 Terrace Street, Pittsburgh, Pennsylvania, 15261, USA

    Michael K. Dishart &  John A. Kellum

Authors
  1. Michael K. Dishart
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. John A. Kellum
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to John A. Kellum.

Rights and permissions

Reprints and Permissions

About this article

Cite this article

Dishart, M.K., Kellum, J.A. An Evaluation of Pharmacological Strategies for the Prevention and Treatment of Acute Renal Failure. Drugs 59, 79–91 (2000). https://doi.org/10.2165/00003495-200059010-00005

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.2165/00003495-200059010-00005

Keywords

  • Glomerular Filtration Rate
  • Acute Renal Failure
  • Calcium Antagonist
  • Renal Blood Flow
  • Loop Diuretic